1. Home
  2. ACAD vs SHC Comparison

ACAD vs SHC Comparison

Compare ACAD & SHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$17.18

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Logo Sotera Health Company

SHC

Sotera Health Company

N/A

Current Price

$15.94

Market Cap

5.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
SHC
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.2B
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
ACAD
SHC
Price
$17.18
$15.94
Analyst Decision
Buy
Buy
Analyst Count
20
10
Target Price
★ $30.21
$21.44
AVG Volume (30 Days)
2.4M
★ 2.5M
Earning Date
11-04-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.12
68.75
EPS
★ 0.51
0.48
Revenue
$726,437,000.00
★ $1,163,617,000.00
Revenue This Year
$19.55
$6.90
Revenue Next Year
$13.34
$5.48
P/E Ratio
$34.47
★ $33.77
Revenue Growth
★ 40.45
5.74
52 Week Low
$15.86
$13.09
52 Week High
$30.96
$19.85

Technical Indicators

Market Signals
Indicator
ACAD
SHC
Relative Strength Index (RSI) 34.82 36.02
Support Level $15.86 $14.93
Resistance Level $22.71 $16.41
Average True Range (ATR) 1.20 0.57
MACD -0.11 -0.02
Stochastic Oscillator 18.38 15.60

Price Performance

Historical Comparison
ACAD
SHC

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About SHC Sotera Health Company

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.

Share on Social Networks: